Long-duration Parkinson's disease: Role of lateralization of motor features
A mean of 10 years elapse before patients with Parkinson's disease (PD) reach Hoehn & Yahr (H&Y) stage 4, and 14 years for stage 5. A small proportion of PD patients survive and are ambulatory for ≥20 years. We sought to identify features associated with long-duration PD (dPD). This fiv...
        Saved in:
      
    
          | Published in | Parkinsonism & related disorders Vol. 19; no. 1; pp. 77 - 80 | 
|---|---|
| Main Authors | , , , , , , , | 
| Format | Journal Article | 
| Language | English | 
| Published | 
        England
          Elsevier Ltd
    
        01.01.2013
     | 
| Subjects | |
| Online Access | Get full text | 
| ISSN | 1353-8020 1873-5126 1873-5126  | 
| DOI | 10.1016/j.parkreldis.2012.07.008 | 
Cover
| Summary: | A mean of 10 years elapse before patients with Parkinson's disease (PD) reach Hoehn & Yahr (H&Y) stage 4, and 14 years for stage 5. A small proportion of PD patients survive and are ambulatory for ≥20 years. We sought to identify features associated with long-duration PD (dPD).
This five-center, case–control study compared 136 PD patients with ≥20 years of duration and H&Y stage ≤4 (dPD) to 134 H&Y-, age- and gender-matched PD patients between 10 and 15 years of disease (cPD).
By study design, there were no between-group differences in age, gender and H&Y. dPD subjects were younger at onset (p < 0.0001), had more psychosis (p: 0.038), were receiving higher levodopa equivalent daily doses (p: 0.02), were predominantly left-handed (p: 0.048), and had greater frequency of left-sided onset (p: 0.015) compared to cPD subjects. Both groups had similar rates of resting tremor, dementia and REM sleep behavior disorder.
Early disease onset, left-handedness and left-sided onset are associated with long disease and ambulatory PD survival. The neurobiological basis of the prognostic value of lateralization deserves further investigation. | 
|---|---|
| Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 Dr. Munhoz has received grants from Novartis, Roche, Boehringer Ingelheim, and Ipsen. Dr Espay is a consultant for Chelsea Therapeutics, is part of the advisory boards of Solvay, Abbott, Chelsea Therapeutics, TEVA, and Eli Lilly, has received honoraria from Novartis, American Academy of Neurology, and Movement Disorders Society, receives salary support from grants from the NIH (1K23MH092735), CleveMed/Great Lakes, Neurotechnologies, and Michael J Fox Foundation, and royalties from Lippincott Williams & Wilkins. Dr Morgante has received honoraria from Personal compensation for educational activities with Boehringer Ingelheim, Lundbeck, Novartis, Chiesi Farmaceutici, GlaxoSmithKline and UCB pharma, and grants from Neureca – Onlus, Milan. Dr. Teive has received speaking honoraria from Allergan, Boeringher-Ingelheim, Ipsen, Roche, and Novartis, and is part of the Editorial board of Parkinsonism and Related Disorders Journal, Journal of Neurology Research, Parkinson’s Disease Journal, Current Neurology and Neuroscience Reports, and Arquivos de Neuro-Psiquiatria. Dr Litvan has received grants from the NIH (5R01AG024040), National Parkinson Foundation, Parkinson Support Center of Kentuckiana, CurePSP, and has contracts with Parkinson Study Group, Noscira, and Allon Therapeutic. Drs Li, Dunn and Gallin have nothing to disclose. Financial disclosure  | 
| ISSN: | 1353-8020 1873-5126 1873-5126  | 
| DOI: | 10.1016/j.parkreldis.2012.07.008 |